logo
Exercise boosts survival rates in colon cancer patients, study shows

Exercise boosts survival rates in colon cancer patients, study shows

A three-year exercise program improved survival in colon cancer patients and kept disease at bay, a first-of-its-kind international experiment showed.
With the benefits rivaling some drugs, experts said cancer centers and insurance plans should consider making exercise coaching a new standard of care for colon cancer survivors. Until then, patients can increase their physical activity after treatment, knowing they are doing their part to prevent cancer from coming back.
'It's an extremely exciting study,' said Dr. Jeffrey Meyerhardt of Dana-Farber Cancer Institute, who wasn't involved in the research. It's the first randomized controlled trial to show how exercise can help cancer survivors, Meyerhardt said.
Prior evidence was based on comparing active people with sedentary people, a type of study that can't prove cause and effect. The new study — conducted in Canada, Australia, the United Kingdom, Israel and the United States — compared people who were randomly selected for an exercise program with those who instead received an educational booklet.
'This is about as high a quality of evidence as you can get,' said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology. 'I love this study because it's something I've been promoting but with less strong evidence for a long time.'
The findings were featured Sunday at ASCO's annual meeting in Chicago and published by the New England Journal of Medicine. Academic research groups in Canada, Australia and the U.K. funded the work.
Researchers followed 889 patients with treatable colon cancer who had completed chemotherapy. Half were given information promoting fitness and nutrition. The others worked with a coach, meeting every two weeks for a year, then monthly for the next two years.
Coaches helped participants find ways to increase their physical activity. Many people, including Terri Swain-Collins, chose to walk for about 45 minutes several times a week.
'This is something I could do for myself to make me feel better,' said Swain-Collins, 62, of Kingston, Ontario. Regular contact with a friendly coach kept her motivated and accountable, she said. 'I wouldn't want to go there and say, 'I didn't do anything,' so I was always doing stuff and making sure I got it done.'
After eight years, the people in the structured exercise program not only became more active than those in the control group but also had 28% fewer cancers and 37% fewer deaths from any cause. There were more muscle strains and other similar problems in the exercise group.
'When we saw the results, we were just astounded,' said study co-author Dr. Christopher Booth, a cancer doctor at Kingston Health Sciences Centre in Kingston, Ontario.
Exercise programs can be offered for several thousand dollars per patient, Booth said, 'a remarkably affordable intervention that will make people feel better, have fewer cancer recurrences and help them live longer.'
Researchers collected blood from participants and will look for clues tying exercise to cancer prevention, whether through insulin processing or building up the immune system or something else.
Swain-Collins' coaching program ended, but she is still exercising. She listens to music while she walks in the countryside near her home.
That kind of behavior change can be achieved when people believe in the benefits, when they find ways to make it fun and when there's a social component, said paper co-author Kerry Courneya, who studies exercise and cancer at the University of Alberta. The new evidence will give cancer patients a reason to stay motivated.
'Now we can say definitively exercise causes improvements in survival,' Courneya said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fresh, rested Oilers feel ready for Stanley Cup Final — perhaps none more than Evander Kane
Fresh, rested Oilers feel ready for Stanley Cup Final — perhaps none more than Evander Kane

New York Times

time2 hours ago

  • New York Times

Fresh, rested Oilers feel ready for Stanley Cup Final — perhaps none more than Evander Kane

EDMONTON – Even without injured right winger Zach Hyman, the Edmonton Oilers feel better prepared to handle the Florida Panthers in the Stanley Cup Final than they did a year ago. The collective health of the rest of the group is a big reason for that optimism. 'It's not just injuries,' Oilers coach Kris Knoblauch said. 'We've been able to play fewer games. We've had long breaks between two series. Last year, we never had that. The seven-game series against Vancouver was tough. Dallas, it felt like it took a much bigger toll on us. Advertisement 'Overall, I'd say we're in a little bit better position physically.' That starts with Evander Kane. 'It's fun to be a part of it and not have any question marks,' he said. Kane played through the 2024 playoffs with a sports hernia and was a shell of his best self. He stood up on the bench during games because it was too painful to sit down. He had only 4 minutes, 39 seconds, of ice time when the Oilers closed out the Dallas Stars in Game 6 in the Western Conference final. He was done by time the Stanley Cup Final shifted to Edmonton. 'It was not fun,' Kane said. 'You're getting needles on off days just to be able to walk around. 'That was last year. I'm really excited we get another crack at it this year and feeling the way I'm feeling.' Kane has been a difference-maker for the Oilers this postseason. He made his season debut in Game 2 of the first-round series against the Los Angeles Kings after missing the entire regular season following core surgeries in September and a knee scope in January. He's since played up and down the lineup, recording five goals and 11 points in 15 games. He's had some signature moments, including a pair of one-goal, one-assist efforts in the first and second rounds. He scored an insurance marker in Game 5 of the Western Conference final last Thursday with Hyman out of commission after he underwent surgery for an upper-body injury. The Oilers, without Hyman, will need the best of Kane against the Panthers. He believes he's ready for that challenge, especially after missing most of the Final last June. He'll be expected to play with an edge, intimidate and perhaps provide the antidote to Panthers pest Matthew Tkachuk, as he did in the 2022 series against the Calgary Flames. 'I've been in the league 16 years. I think I've shown that I enjoy that side of the game,' Kane said, smiling. 'It's part of the competitiveness, part of the spirit of the NHL playoffs. It's something that I enjoy. At the same time, you want to be smart with it and make sure you're playing hockey first.' Advertisement Kane could be a catalyst in this series. He moved up to the second line with Leon Draisaitl and Kasperi Kapanen when Hyman left the lineup. He's expected to remain in a top-six role to start the Final. But the Oilers have more than just Kane to offset Hyman's loss. Knoblauch said Connor Brown will return to the lineup for the Final opener after missing the last two games of the Dallas series because he was hit by Alex Petrovic in Game 3. Combine Brown with the added depth, and Hyman's loss isn't nearly the issue that would have been in past seasons. 'We're better equipped this year, especially up front — a lot more physical players,' Knoblauch said. 'We did a great job in Game 5 against Dallas,' Kane said. 'This time around, we have a lot more depth throughout the entirety of our lineup. If we need scoring, we have scoring. If we need some guys that can be a little more physical, we can be more physical. Unfortunately, we're going to have to use that depth, and we're going to have to get the job done with it.' On defense, getting Mattias Ekholm back is a huge boost. He played just short of 16 minutes in his return from a lower-body injury in Game 5 — his 2025 postseason debut and his first appearance since April 11 — while recording an assist and two blocked shots and taking a penalty. 'He looked a lot like we're accustomed to seeing Ekky play,' Oilers coach Kris Knoblauch said. Knoblauch expects him to be closer to his 22:12 average from the regular season in Game 1 of the Final. The initial prognosis for Ekholm, after his second failed attempt to return from his injury, was that he'd miss the entire postseason. But now the injury is not even on his mind. 'It's been feeling good for a couple weeks, but you've also got to get beyond that mental thing where you trust it and you can go 100 percent in every situation and not think so much,' Ekholm said. 'I feel really good, and I feel like I trust my body.' Advertisement The one advantage for the Oilers, at least compared to a year ago, is they don't need to tax Ekholm if it's not necessary. They can spread around the ice time and duties more evenly. They might have their best and most well-rounded group of defensemen since the glory days of the 1980s. 'We have a D corps that can move the puck, that can skate,' Darnell Nurse said. 'We have elements of physicality and compete. I like our group. I really do like the six guys that can go out there. 'We've showed, too, over the course of the playoffs, that we've had guys waiting to get in the lineup that can make an impact as well.' Ekholm was back with usual partner Evan Bouchard in the Western Conference final clincher, whereas Darnell Nurse and Brett Kulak were paired together, as were Jake Walman with John Klingberg. The blue line has undergone quite the transformation with Walman and Klingberg in the mix – plus extras Troy Stecher and Ty Emberson – compared to having Cody Ceci, Vincent Desharnais and Philip Broberg a year ago. 'Nothing against our defense last year. There's a little bit of a changeover,' Knoblauch said. 'They way these guys are playing right now and the personnel we have with the types of players, we like that.' With Ekholm being eased back into the lineup last game, ice times ranged from Klingberg's 17:29 to Kulak's 22:32. 'You look at the two D corps, and I thought we had a good D corps last year as well,' Ekholm said. 'But this year, we're different. We're more mobile. We have three pairs that can play against top lines. They can play against bottom lines. We can all do it. 'Knowing that every pair can contribute both offensively and defensively is hopefully something that'll be in our favor.' It's not as though everyone is completely healthy entering the Stanley Cup Final. Advertisement The Oilers had many players sidelined as the regular season ended and, although they all returned, playoff hockey doesn't exactly tickle. Brown is recovering from his injury. McDavid left Sunday's practice, though Knoblauch said he'll be back on the ice with his teammates on Tuesday. Still, the Oilers believe they're in a better spot than they were a year ago. Having Kane play at closer to his 2022 postseason level, when he was scoring goals and getting under opponents' skins, compared to last year's form goes a long way. 'Do I think he can make a difference? Absolutely,' Knoblauch said. 'We missed him last year. I think he'll be a big part of this series now.' (Photo of Evander Kane: Leila Devlin / Getty Images)

I became a widow at 35. Here's what I want people to know about dating after the death of your spouse
I became a widow at 35. Here's what I want people to know about dating after the death of your spouse

Yahoo

time2 hours ago

  • Yahoo

I became a widow at 35. Here's what I want people to know about dating after the death of your spouse

In October 2021, Whitney Lyn Allen was pregnant with her second child when her husband, Ryan, died following complications from a severe allergic reaction to a bee sting. The former attorney-turned-grief counsellor's life was upended by loss. But she embraced the possibility of love again and recently remarried in January 2025. "There are many reasons people want to date after losing a spouse," Allen said in an interview withYahoo Canada. "It's the most natural thing in the world, especially if you've had a healthy relationship or marriage. To crave emotional, mental and physical stability and intimacy again is completely normal." Much like divorce, the idea of getting back into the dating game after the death of a spouse can be daunting. However, unlike a divorce, people who are widowed didn't choose for their relationship to end; grief can complicate their feelings about heading into a new phase of life and potentially meeting someone new. But how do you begin the process of finding love? We asked Allen as well as Krista Roesler, a Toronto-based registered psychologist, to weigh in. Allen and Roesler both receive questions about dating after loss, but one of the most common questions people have usually surrounds timing. Some might ask, "How do you know when you're ready to date again?" Allen said a better question might be whether you have a "healthy curiosity around the experience of opening up your heart again," even at the risk of heartbreak. I wanted to feel alive again, to have a night where I wasn't just a widow or a Lyn Allen "It means you're opening up your heart again to possibly be hurt, whether through a breakup or another loss," she said. Roesler said it's best to take time to process your emotions before stepping back into dating. "It's important to progress to the acceptance stage of grief. Once the feelings become less intense, you may have the space to welcome someone new into your life," she explained. For Allen, who's the author of "Running in Trauma Stilettoes: A Raw Glimpse at Grief and Life After Loss," the decision to move forward was intentional. She met her now-husband, Anthony Gadecki, on a dating app. "I was curious about the dating scene. I wanted to feel alive again, to have a night where I wasn't just a widow or a mom. I didn't expect to find my next husband so soon, but when you meet someone who makes sense, it just happens." People may be surprised by how often they make comparisons between their new partner and their deceased spouse. Allen said this is common and completely normal. "You're human. ... Making comparisons doesn't mean one person or relationship is better than another. It's human nature and it's going to happen." Finding someone who will be understanding and sensitive to your grief is key. Allen said there are times when the person grieving will need more support, especially during difficult times like anniversaries or birthdays. "It's about allowing yourself to accept this new life, the new love for this new person, while also letting the love for the person who's no longer here coexist," she explained, adding that being in a new relationship doesn't diminish the love for the one lost. "It's not a competition; both loves can exist at once." Allen said Gadecki has been steady in his support, but acknowledges she alone was "responsible for her grief." Open communication was key to their bond. "I expressed what I needed; he's not a mind reader. We had honest conversations and realistic expectations, even when it meant tackling uncomfortable topics," she added. It's not a competition; both loves can exist at Lyn Allen "But at the end of the day, he chose me and my boys, fully aware of the complexities that come with being part of a family living with grief and trauma." Roesler said it's key for couples to be able to talk about loss without their partner taking it personally. "Be patient and avoid having any expectations about the process. It will take time, and they might not have much to give while coping with the loss." Building a new relationship while grieving the loss of a previous partner can be challenging. However, it's not about balancing but allowing both relationships to coexist. "It's giving yourself grace to feel intense emotions and having the courage to be honest in your new relationship about what you're feeling and what you need," Allen said. Unfortunately, it's not uncommon for people to receive judgment from friends and family once they begin dating again. Roesler said it's important to understand it's their problem, not yours. "You can't please everyone. Your job isn't to please anyone but yourself," she explained. "The person who matters most in this choice is you because you are the only one who has to live your life and deal with the consequences." View this post on Instagram A post shared by WHITNEY LYN | AUTHOR & GRIEF COACH FOR WIDOWS🖤 (@whitneylynallen) Along with publishing two books on loss, Allen has chosen to document her grief through social media. Though her close family was supportive of her moving forward, the outside world wasn't always as kind and she's been subjected to criticism by strangers on the internet. "Comments like 'you must not have loved your husband' or questioning if my baby was my husband's — just unkind things. It's absurd," she said. "There's no perfect amount of time to start dating again, and it's not for anyone else to determine. "Some people believe that widows and widowers should remain single out of loyalty and respect for their deceased partner. I disagree. I think love and respect can be found in new relationships."

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Yahoo

time4 hours ago

  • Yahoo

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 months Continued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be further evaluated in a planned Phase 3 trial Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months, treatment with Rina-S 100 mg/m2 every 3 weeks (Q3W) resulted in a 50.0 percent confirmed objective response rate (ORR), including two complete responses (CR), in heavily pre-treated advanced endometrial cancer (EC) patients who experienced disease progression on or after treatment with platinum-based chemotherapy and an immune checkpoint inhibitor. The median duration of response (mDOR) was not reached. These data are from the endometrial cancer monotherapy dose expansion B2 cohort of the multi-part RAINFOL-01 trial evaluating the safety and efficacy of Rina-S in solid tumors and were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. 'Advanced stage and recurrent endometrial cancer often lead to resistance to standard of care options. When this occurs, prognosis worsens and treatment options become increasingly limited, leaving patients and clinicians to navigate difficult decisions,' said Ira Winer, M.D., Ph.D., FACOG, study investigator and Professor, Division of Gynecologic Oncology and Phase I Developmental Therapeutics at the Karmanos Cancer Institute, Wayne State University. 'These Phase 1/2 results demonstrate encouraging data with Rina-S in this patient population and support its further development as a potential therapy for patients with advanced and recurrent endometrial cancer.' The B2 cohort of the Phase 1/2 RAINFOL-01 study (NCT05579366) is a dose expansion cohort evaluating the efficacy and safety of Rina-S in patients with advanced or recurrent endometrial cancer. In the study, 64 patients with heavily pretreated advanced or recurrent endometrial cancer whose disease had progressed on or after an anti-PD-(L)1 and platinum-based chemotherapy were enrolled and treated with Rina-S. Patients were administered either 100 mg/m2 (n=22) or 120 mg/m2 (n=42) of Rina-S. In the 100 mg/m2 cohort, the confirmed ORR was 50.0 percent, including two CRs. Anti-tumor activity was also observed in patients treated with Rina-S 120 mg/m2 Q3W, which resulted in 47.1 percent confirmed ORR. The mDoR was not reached after a median follow-up of 7.7 months in the 100 mg/m2 cohort and a median follow-up of 9.8 months in the 120 mg/m2 cohort. Median age was 67.0 years and 69.5 years in the 100 mg/m2 and 120 mg/m2 cohorts, respectively. Study participants were previously treated with a median of three lines of therapy (range 1-8). Common treatment emergent adverse events (TEAEs; all grades) included diarrhea, shortness of breath (dyspnea), urinary tract infection, headache, constipation, decreased appetite, vomiting, fatigue and nausea. Serious TEAEs (Grade 3 or higher) occurred in 31.8 percent and 50.0 percent of patients treated with Rina-S 100 mg/m2 and 120 mg/m2, respectively. Hematologic adverse events were manageable without significant dose reduction and with low rates of treatment discontinuation. No signals of ocular toxicities, neuropathy or Interstitial Lung Disease (ILD) were observed. Ocular toxicities and ILD are often reported as adverse events associated with ADCs i,ii,iii,iv. 'Rina-S represents the kind of innovation that defines our focus at Genmab, which is to develop wholly owned, novel antibody-based medicines that have the potential to transform the treatment of cancer and address an unmet need, including for patients with advanced endometrial cancer,' said Judith Klimovsky, M.D., Executive Vice President and Chief Development Officer of Genmab. 'The encouraging early signals in endometrial cancer underscore our deep commitment to making a meaningful impact for women with gynecologic cancers, where treatment advances have long lagged behind the need.' About the RAINFOLTM -01 TrialRAINFOL-01 (NCT05579366) is an open-label, multicenter Phase 1/2 study, designed to evaluate the safety and efficacy of rinatabart sesutecan (Rina-S) Q3W at various doses in solid tumors that are known to express FRα. The study consists of multiple parts including Part A monotherapy cohorts; Part B tumor-specific monotherapy dose-expansion cohorts; Part C platinum-resistant ovarian cancer (PROC) cohort; Part D combination therapy cohorts; and Part F a monotherapy endometrial cancer (EC) cohort. About Endometrial CancerEndometrial cancer (EC) ranks as the second most prevalent gynecologic cancer globally, with increasing incidence and mortality ratesv,vi, highlighting the need for effective management strategies. Patients with advanced or recurrent EC have a relatively poor prognosis and treatment options are limited for those patients who have progressed following treatment with chemotherapy and immune checkpoint inhibitor. FRα is overexpressed on multiple tumors, including EC, making it a promising therapeutic target. Anti-tumor activity with Rina-S was observed across a broad range of FRα expression, and there are currently no approved FRα-targeting therapies approved for the treatment of endometrial cancer. EC starts in the lining of the uterus, known as the Patients with advanced or recurrent endometrial cancer have a high unmet need. Most (64-74 percent) patients with EC experience disease progression on immune checkpoint inhibitors (ICI) plus chemotherapy irrespective of biomarker status. Treatment options after progression on an ICI-regimen are very limited and consist of single-agent chemotherapy (ORR <16 percent and median progression-free survival [PFS] <5 months). About Rinatabart Sesutecan (Rina-S; GEN1184)Rinatabart sesutecan (Rina-S; GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at folate receptor α (FRα), a novel hydrophilic protease-cleavable linker, and exatecan, a topoisomerase I inhibitor payload. The clinical trial program for Rina-S continues to expand including ovarian, endometrial and other cancers of unmet need. In January 2024, the U.S. Food and Drug Administration granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer. Rina-S is advancing through late-stage development, supported by a growing portfolio of Phase 2 and Phase 3 trials, including further evaluation of single-agent Rina-S in patients with advanced endometrial cancer in Part F of the ongoing RAINFOL™-01 trial and in a planned Phase 3 trial. The safety and efficacy of rinatabart sesutecan has not been established. Please visit for more information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and X. Contact: David Freundel, Senior Director, Global Communications & Corporate AffairsT: +1 609 613 0504; E: dafr@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ This Media Release contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. i Li BT, Meric-Bernstam F, Bardia A, et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 2024;25(6):707-719. (In eng). DOI: 10.1016/s1470-2045(24) Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-2174. (In eng). DOI: 10.1056/ Vergote I, González-Martín A, Fujiwara K, et al. Tisotumab vedotin as second- or third-line therapy forrecurrent cervical cancer. N Engl J Med 2024;391(1):44-55. (In eng). DOI: 10.1056/ Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2020;183(1):23-39. (In eng). DOI: 10.1007/s10549-020-05754-8.v Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: Cancer today (version 1.1). International Agencyfor Research on Cancer. 05/28/2024 ( Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021;31(1):12-39. (In eng). DOI: 10.1136/ Mayo Clinic. Endometrial Cancer. Accessed May 2025. Media Release no. i12CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 ValbyDenmarkAttachment 020625_i12_ASCO 2025 Rina-S EC MRError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store